Full Prescribing Information, Including BOXED WARNING
Read About Twirla
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)
Agile Therapeutics® Partners with Award-Winning Director Maya Albanese on First Twirla® Commercial, Targeting Gen Z
Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. All current Agile Therapeutics product and product candidates use our proprietary Skinfusion® Technology.
Commitment. Passion. Drive.
These are the qualities that make us who we are, from the top down.
©2021 Agile Therapeutics®. All Rights Reserved.
View a snapshot of our consumer advertising